says MorphoSys' Simon Moroney in an interview with Wolf Kroner, and explains his strategy in Asia, his experiences with royalty provisions in pharma deals, litigation over IP, and prospects of integrating Serotec.

To access this article, please click on your left "Subscription". Thank you.